Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants (IMPACT)

A Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Impact of Auryxia (Ferric Citrate) on Erythropoiesis-Stimulating Agent (ESA) Use, Intravenous (IV) Iron Use, Phosphate Control, and Anemia Control in Adult Participants on In-Center Hemodialysis or Home Dialysis

This study is being conducted to demonstrate the effect of Auryxia, when used as the primary phosphate lowering therapy, on the overall cumulative use of erythropoiesis-stimulating agent and intravenous iron as well as on the laboratory parameters indicative of phosphate and anemia management.

Study Overview

• Status: Completed
• Conditions: Renal Insufficiency; Hyperphosphatemia; Anemia, Iron Deficiency
• Intervention / Treatment: Drug: Ferric Citrate 1 gram Oral Tablet; Drug: Standard of care phosphate-lowering therapy

Detailed Description

Approximately 200 participants will be randomized 1:1 (stratified by modality and hemoglobin level) to receive either Auryxia or standard of care phosphate lowering therapy to determine the impact of Auryxia when used as the primary phosphate lowering therapy as compared to standard of care on the utilization of erythropoiesis-stimulating agent and intravenous iron in both in-center and home dialysis populations. This study will also seek to determine the impact of Auryxia, when used as the primary phosphate lowering therapy versus standard of care, on the biochemical assessments of serum phosphate and hemoglobin in both in-center and home dialysis populations.

• Study Type: Interventional
• Enrollment (Actual): 214
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Alaska
    • Anchorage, Alaska, United States, 99515
      • US Renal Care - Dimond
  • Arizona
    • Mesa, Arizona, United States, 85210
      • US Renal Care - Mesa
  • Arkansas
    • Pine Bluff, Arkansas, United States, 71603
      • US Renal Care - Pine Bluff
  • California
    • Granada Hills, California, United States, 91325
      • US Renal Care - Northridge Roscoe
  • Georgia
    • Dalton, Georgia, United States, 30720
      • US Renal Care - Dalton
  • Indiana
    • Shelbyville, Indiana, United States, 46176
      • US Renal Care - Major Health
  • New Mexico
    • Gallup, New Mexico, United States, 87301
      • US Renal Care - Red Rocks
  • Texas
    • Dallas, Texas, United States, 75231
      • US Renal Care - North Dallas
    • Dallas, Texas, United States, 75237
      • Dallas Renal Group
    • San Antonio, Texas, United States, 78251
      • US Renal Care - Westover Hills
    • San Antonio, Texas, United States, 78202
      • US Renal Care - Houston Street
    • San Antonio, Texas, United States, 78221
      • US Renal Care - Palo Alto
    • San Antonio, Texas, United States, 78221
      • US Renal Care - Pleasanton Rd.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Adult participants greater or equal to 18 years old.
2. Diagnosis of end-stage kidney disease and receiving maintenance dialysis (in-center, home hemodialysis or peritoneal dialysis) for greater or equal to 12 weeks prior to randomization.
3. Most recent transferrin saturation less than or equal to 50 percent
4. Most recent serum phosphate is greater or equal to 3.0 milligrams per deciliter
5. Receiving treatment for greater or equal to 8 weeks prior to screening with non-Auryxia phosphate lowering therapy. No requirement for stable dosing within this time frame.
6. Receiving treatment for greater or equal to 8 weeks prior to screening with erythropoiesis-stimulating agent (any dose, any type). No requirement for stable dosing within this time frame.
7. Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure.

Exclusion Criteria:

1. A known allergy or intolerance to Auryxia or any of its constituents.
2. Hypersensitivity reaction to previous oral iron therapy.
3. History of hemochromatosis or other iron overload syndrome.
4. Active malignancy requiring current treatment except for non-melanoma skin cancer regardless of treatment.
5. Active drug or alcohol dependence or abuse (excluding tobacco use or medicinal or recreational marijuana) within the 12 months prior to Screening or evidence of such abuse (in the opinion of the Investigator).
6. Limited life expectancy (less than 6 months), (in the opinion of the Investigator).
7. Scheduled organ transplant and participants on the kidney transplant wait-list who are expected to receive a transplant within 6 months of screening. Being active on transplant list is not an exclusion. Previous kidney transplant is not an exclusion.
8. Unable to comply with study requirements or in the opinion of the Investigator not clinically stable to participate in the study.
9. Females who are known to be pregnant or are breast-feeding during Screening or are planning to become pregnant and breastfeeding during the study period.
10. Evidence of clinically active infection at the time of Screening.
11. Use of an investigational medication or participation in an investigational study within 30 days prior to Screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Ferric citrate (commercially available, Auryxia); Ferric citrate, (commercially available Auryxia), supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron). Administered orally with meals or snacks.	Drug: Ferric Citrate 1 gram Oral Tablet; Ferric citrate is an iron-based phosphate binder for the treatment of hyperphosphatemia in subjects with dialysis-dependent chronic kidney disease (DD CKD) and for the treatment of iron deficiency anemia (IDA) in subjects with non-dialysis dependent chronic kidney disease (NDD CKD).; Other Names: Auryxia
ACTIVE_COMPARATOR: Standard of care phosphate lowering therapy; Non-Auryxia phosphate-lowering therapy administered as standard of care.	Drug: Standard of care phosphate-lowering therapy; Subjects randomized to SOC will continue their currently prescribed dose of phosphate lowering therapy which will be dosed per local standard of care to achieve community target serum phosphate goals.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in mean dose of erythropoiesis-stimulating agent (standardized Units per month) between Auryxia and standard of care treatment groups	Difference in change from baseline period (Month -3 to Day 1) to months 4 to 6 (efficacy evaluation period) in mean dose of erythropoiesis-stimulating agent (standardized Units per month) between Auryxia and standard of care treatment groups.	Baseline period (Month -3 to Day 1) to months 4to 6 (efficacy evaluation period)
Difference in mean dose of intravenous iron (milligram per month) between Auryxia and standard of care treatment groups.	Difference in change from baseline period to efficacy evaluation period in mean dose of intravenous iron (milligrams per month) between Auryxia and standard of care treatment groups.	Baseline period (Month -3 to Day 1) to months 4 to6 (efficacy evaluation period)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in hemoglobin measurements	Difference in proportion of measurements with hemoglobin at or above 10.0 grams per deciliter between Auryxia and standard of care treatment groups during efficacy evaluation period.	Baseline period (Month -3 to Day 1) to months 4to6 (efficacy evaluation period).
Difference in serum phosphate measurements	Difference in proportion of measurements with serum phosphate at or below 5.5 milligrams per deciliter between Auryxia and standard of care treatment groups during efficacy evaluation period.	Baseline period (Month -3 to Day 1) to months 4to6 (efficacy evaluation period)

Collaborators and Investigators

• Sponsor: USRC Kidney Research
• Collaborators: Akebia Therapeutics Inc.

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 29, 2021
• Primary Completion (ACTUAL): September 15, 2022
• Study Completion (ACTUAL): September 15, 2022

Study Registration Dates

• First Submitted: June 8, 2021
• First Submitted That Met QC Criteria: June 8, 2021
• First Posted (ACTUAL): June 10, 2021

Study Record Updates

• Last Update Posted (ACTUAL): November 7, 2022
• Last Update Submitted That Met QC Criteria: November 3, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Kidney Diseases; Urologic Diseases; Hematologic Diseases; Anemia, Hypochromic; Iron Metabolism Disorders; Phosphorus Metabolism Disorders; Anemia, Iron-Deficiency; Renal Insufficiency; Anemia; Hyperphosphatemia
• Other Study ID Numbers: USRC-2021-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No